Concepts (371)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thalamus | 53 | 2020 | 131 | 11.570 |
Why?
|
| Geniculate Bodies | 108 | 2019 | 138 | 8.660 |
Why?
|
| Cerebral Cortex | 29 | 2021 | 569 | 5.540 |
Why?
|
| Somatosensory Cortex | 19 | 2019 | 109 | 4.930 |
Why?
|
| Neural Pathways | 44 | 2020 | 324 | 4.920 |
Why?
|
| Neurons | 68 | 2019 | 1568 | 4.470 |
Why?
|
| Thalamic Nuclei | 18 | 2017 | 32 | 3.860 |
Why?
|
| Auditory Cortex | 13 | 2018 | 66 | 3.830 |
Why?
|
| Synapses | 34 | 2018 | 274 | 3.740 |
Why?
|
| Receptors, Metabotropic Glutamate | 17 | 2015 | 50 | 3.590 |
Why?
|
| Visual Cortex | 40 | 2018 | 244 | 2.910 |
Why?
|
| Cats | 104 | 2007 | 281 | 2.810 |
Why?
|
| Nerve Net | 14 | 2021 | 394 | 2.710 |
Why?
|
| Visual Pathways | 55 | 2018 | 151 | 2.690 |
Why?
|
| Neural Inhibition | 18 | 2015 | 104 | 2.200 |
Why?
|
| Brain Mapping | 28 | 2017 | 565 | 1.980 |
Why?
|
| Animals | 181 | 2021 | 27973 | 1.930 |
Why?
|
| Axons | 27 | 2011 | 176 | 1.870 |
Why?
|
| Mice, Inbred BALB C | 27 | 2015 | 1099 | 1.870 |
Why?
|
| Synaptic Transmission | 19 | 2014 | 223 | 1.720 |
Why?
|
| In Vitro Techniques | 27 | 2017 | 944 | 1.510 |
Why?
|
| Photic Stimulation | 29 | 2015 | 506 | 1.420 |
Why?
|
| Patch-Clamp Techniques | 22 | 2019 | 378 | 1.390 |
Why?
|
| Interneurons | 15 | 2015 | 106 | 1.380 |
Why?
|
| Excitatory Postsynaptic Potentials | 15 | 2013 | 86 | 1.380 |
Why?
|
| Electric Stimulation | 33 | 2019 | 344 | 1.330 |
Why?
|
| Auditory Pathways | 5 | 2012 | 35 | 1.290 |
Why?
|
| Glutamic Acid | 12 | 2016 | 135 | 1.280 |
Why?
|
| Retina | 29 | 2013 | 212 | 1.270 |
Why?
|
| Action Potentials | 28 | 2015 | 578 | 1.230 |
Why?
|
| Mice | 36 | 2020 | 12230 | 1.210 |
Why?
|
| Efferent Pathways | 6 | 2018 | 22 | 1.170 |
Why?
|
| Brain Stem | 12 | 2002 | 163 | 0.940 |
Why?
|
| Vision, Ocular | 20 | 2005 | 73 | 0.880 |
Why?
|
| Afferent Pathways | 11 | 2013 | 63 | 0.870 |
Why?
|
| GABAergic Neurons | 2 | 2015 | 19 | 0.850 |
Why?
|
| Visual Perception | 25 | 2003 | 333 | 0.790 |
Why?
|
| Behavior | 2 | 2021 | 85 | 0.770 |
Why?
|
| Ventral Thalamic Nuclei | 2 | 2015 | 6 | 0.750 |
Why?
|
| Feedback, Physiological | 3 | 2013 | 66 | 0.730 |
Why?
|
| Presynaptic Terminals | 5 | 2018 | 41 | 0.730 |
Why?
|
| Dendrites | 17 | 2010 | 97 | 0.720 |
Why?
|
| Sensory Deprivation | 23 | 2001 | 32 | 0.700 |
Why?
|
| Cognition | 3 | 2019 | 625 | 0.680 |
Why?
|
| Flavoproteins | 5 | 2011 | 24 | 0.650 |
Why?
|
| Neurosciences | 2 | 2018 | 51 | 0.630 |
Why?
|
| Electrophysiology | 26 | 2008 | 389 | 0.590 |
Why?
|
| Mesencephalon | 4 | 2010 | 67 | 0.580 |
Why?
|
| Calcium | 13 | 2009 | 1173 | 0.570 |
Why?
|
| Joint Instability | 3 | 2025 | 98 | 0.570 |
Why?
|
| Animals, Newborn | 12 | 2015 | 515 | 0.570 |
Why?
|
| Models, Neurological | 10 | 2013 | 408 | 0.570 |
Why?
|
| Sensorimotor Cortex | 1 | 2018 | 12 | 0.570 |
Why?
|
| Microscopy, Fluorescence | 5 | 2011 | 435 | 0.560 |
Why?
|
| Executive Function | 1 | 2019 | 103 | 0.560 |
Why?
|
| Attention | 2 | 2021 | 410 | 0.550 |
Why?
|
| Excitatory Amino Acid Antagonists | 8 | 2012 | 78 | 0.530 |
Why?
|
| Lasers | 4 | 2011 | 99 | 0.520 |
Why?
|
| Macaca mulatta | 6 | 2003 | 448 | 0.520 |
Why?
|
| Inhibitory Postsynaptic Potentials | 3 | 2015 | 20 | 0.510 |
Why?
|
| Superior Colliculi | 9 | 2009 | 25 | 0.510 |
Why?
|
| Synaptic Potentials | 3 | 2011 | 17 | 0.500 |
Why?
|
| Prosencephalon | 3 | 2013 | 67 | 0.500 |
Why?
|
| Motor Cortex | 2 | 2018 | 209 | 0.490 |
Why?
|
| GABA Antagonists | 7 | 2011 | 26 | 0.480 |
Why?
|
| Intralaminar Thalamic Nuclei | 3 | 2005 | 10 | 0.480 |
Why?
|
| Behavior, Animal | 4 | 2021 | 389 | 0.470 |
Why?
|
| Cycloleucine | 5 | 2003 | 10 | 0.470 |
Why?
|
| gamma-Aminobutyric Acid | 9 | 2007 | 84 | 0.460 |
Why?
|
| Membrane Potentials | 15 | 2009 | 404 | 0.460 |
Why?
|
| Brain | 4 | 2021 | 2337 | 0.430 |
Why?
|
| Nerve Endings | 9 | 2010 | 15 | 0.430 |
Why?
|
| Patellar Dislocation | 2 | 2025 | 15 | 0.420 |
Why?
|
| Calcium Channels | 5 | 2005 | 180 | 0.410 |
Why?
|
| Connectome | 1 | 2015 | 88 | 0.410 |
Why?
|
| Patellofemoral Joint | 2 | 2023 | 19 | 0.400 |
Why?
|
| Biological Evolution | 1 | 2021 | 1019 | 0.400 |
Why?
|
| Retinal Ganglion Cells | 7 | 1995 | 71 | 0.390 |
Why?
|
| Male | 25 | 2025 | 44355 | 0.360 |
Why?
|
| Excitatory Amino Acid Agonists | 4 | 2013 | 43 | 0.350 |
Why?
|
| Rats | 11 | 2009 | 4028 | 0.330 |
Why?
|
| Neuronal Plasticity | 4 | 2014 | 194 | 0.330 |
Why?
|
| Microscopy, Electron | 13 | 2004 | 429 | 0.320 |
Why?
|
| Female | 22 | 2025 | 48542 | 0.320 |
Why?
|
| Visual Fields | 24 | 1995 | 100 | 0.310 |
Why?
|
| Pulvinar | 3 | 2005 | 3 | 0.310 |
Why?
|
| Cholinergic Fibers | 1 | 2010 | 23 | 0.310 |
Why?
|
| Receptors, Muscarinic | 2 | 2007 | 42 | 0.310 |
Why?
|
| S100 Calcium Binding Protein G | 1 | 2009 | 19 | 0.300 |
Why?
|
| Anterior Thalamic Nuclei | 1 | 2009 | 3 | 0.300 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2009 | 67 | 0.300 |
Why?
|
| Tetrodotoxin | 6 | 2007 | 49 | 0.300 |
Why?
|
| Electrophysiological Phenomena | 3 | 2018 | 49 | 0.300 |
Why?
|
| Sensory Receptor Cells | 1 | 2009 | 37 | 0.290 |
Why?
|
| Immunohistochemistry | 9 | 2012 | 1786 | 0.280 |
Why?
|
| Biotin | 2 | 2008 | 44 | 0.280 |
Why?
|
| Rats, Sprague-Dawley | 7 | 2009 | 1236 | 0.280 |
Why?
|
| Lateral Thalamic Nuclei | 2 | 2005 | 4 | 0.280 |
Why?
|
| Neurotransmitter Agents | 2 | 2017 | 101 | 0.280 |
Why?
|
| Humans | 31 | 2025 | 93132 | 0.270 |
Why?
|
| Mice, Transgenic | 3 | 2020 | 1581 | 0.270 |
Why?
|
| Serotonin | 2 | 2008 | 209 | 0.270 |
Why?
|
| Reticular Formation | 2 | 2006 | 17 | 0.260 |
Why?
|
| Sensation | 1 | 2007 | 48 | 0.260 |
Why?
|
| Reaction Time | 9 | 2001 | 316 | 0.250 |
Why?
|
| Olfactory Pathways | 1 | 2006 | 28 | 0.250 |
Why?
|
| Optogenetics | 2 | 2018 | 45 | 0.250 |
Why?
|
| Pre-Exposure Prophylaxis | 2 | 2020 | 186 | 0.240 |
Why?
|
| Neurons, Afferent | 6 | 2010 | 72 | 0.230 |
Why?
|
| Patella | 1 | 2025 | 30 | 0.220 |
Why?
|
| Functional Laterality | 12 | 1988 | 204 | 0.220 |
Why?
|
| Methacholine Chloride | 3 | 2010 | 61 | 0.220 |
Why?
|
| Saccades | 2 | 2003 | 75 | 0.210 |
Why?
|
| Evoked Potentials | 12 | 2002 | 193 | 0.210 |
Why?
|
| Orientation | 8 | 2000 | 111 | 0.210 |
Why?
|
| Computer Simulation | 4 | 2002 | 1120 | 0.200 |
Why?
|
| Microscopy, Confocal | 2 | 2015 | 281 | 0.200 |
Why?
|
| Ankle Injuries | 1 | 2023 | 35 | 0.200 |
Why?
|
| Platelet-Rich Plasma | 1 | 2023 | 13 | 0.200 |
Why?
|
| Horseradish Peroxidase | 12 | 1995 | 34 | 0.200 |
Why?
|
| Models, Biological | 2 | 2008 | 1768 | 0.200 |
Why?
|
| Pyramidal Cells | 2 | 2018 | 86 | 0.200 |
Why?
|
| Pyridazines | 3 | 2009 | 21 | 0.190 |
Why?
|
| Cartilage, Articular | 1 | 2023 | 76 | 0.190 |
Why?
|
| Fractures, Bone | 1 | 2025 | 154 | 0.190 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2015 | 1269 | 0.190 |
Why?
|
| Indomethacin | 2 | 2013 | 58 | 0.190 |
Why?
|
| Muscarinic Agonists | 3 | 2010 | 22 | 0.180 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 2013 | 70 | 0.180 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 3431 | 0.180 |
Why?
|
| Evoked Potentials, Visual | 5 | 1995 | 90 | 0.180 |
Why?
|
| Optic Chiasm | 10 | 1991 | 16 | 0.180 |
Why?
|
| Pancreatitis | 2 | 2013 | 94 | 0.180 |
Why?
|
| Biophysics | 3 | 2011 | 153 | 0.180 |
Why?
|
| Acetylcholine | 3 | 2000 | 158 | 0.170 |
Why?
|
| Electroencephalography | 3 | 2003 | 798 | 0.170 |
Why?
|
| Tobacco Products | 1 | 2021 | 77 | 0.170 |
Why?
|
| Erectile Dysfunction | 1 | 2021 | 77 | 0.170 |
Why?
|
| GABA-A Receptor Antagonists | 2 | 2013 | 14 | 0.160 |
Why?
|
| Fluorescence | 2 | 2011 | 100 | 0.160 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 190 | 0.160 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2021 | 72 | 0.160 |
Why?
|
| HIV Infections | 2 | 2020 | 952 | 0.160 |
Why?
|
| Feedback | 2 | 2006 | 129 | 0.150 |
Why?
|
| Mediodorsal Thalamic Nucleus | 1 | 2019 | 1 | 0.150 |
Why?
|
| Receptors, AMPA | 3 | 2009 | 68 | 0.150 |
Why?
|
| Time Factors | 9 | 2012 | 5380 | 0.150 |
Why?
|
| Anti-HIV Agents | 2 | 2020 | 193 | 0.150 |
Why?
|
| Nitrites | 1 | 2018 | 34 | 0.140 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 3 | 2009 | 87 | 0.140 |
Why?
|
| Transgender Persons | 1 | 2020 | 113 | 0.140 |
Why?
|
| Alzheimer Disease | 1 | 2023 | 600 | 0.140 |
Why?
|
| ROC Curve | 2 | 2002 | 774 | 0.130 |
Why?
|
| Phosphinic Acids | 2 | 2009 | 4 | 0.130 |
Why?
|
| Cholinergic Agents | 1 | 1997 | 17 | 0.130 |
Why?
|
| History, 21st Century | 1 | 2018 | 187 | 0.130 |
Why?
|
| Fluorescent Dyes | 2 | 2012 | 255 | 0.130 |
Why?
|
| Basal Ganglia | 1 | 2017 | 46 | 0.130 |
Why?
|
| History, 20th Century | 1 | 2018 | 312 | 0.120 |
Why?
|
| Dextrans | 2 | 2008 | 77 | 0.120 |
Why?
|
| Iodine Radioisotopes | 1 | 2016 | 137 | 0.120 |
Why?
|
| Space Perception | 6 | 1992 | 112 | 0.120 |
Why?
|
| Radiation Tolerance | 1 | 2016 | 175 | 0.110 |
Why?
|
| Homosexuality, Male | 1 | 2018 | 332 | 0.110 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2016 | 162 | 0.110 |
Why?
|
| Salvage Therapy | 1 | 2016 | 234 | 0.110 |
Why?
|
| Cell Count | 3 | 2012 | 195 | 0.110 |
Why?
|
| Microelectrodes | 3 | 2004 | 86 | 0.110 |
Why?
|
| Carcinoma, Papillary | 1 | 2016 | 159 | 0.110 |
Why?
|
| Cells, Cultured | 2 | 2014 | 2827 | 0.110 |
Why?
|
| Indoles | 1 | 2016 | 298 | 0.110 |
Why?
|
| Sulfonamides | 1 | 2016 | 331 | 0.100 |
Why?
|
| Decision Making | 1 | 2019 | 671 | 0.100 |
Why?
|
| Rhodopsin | 1 | 2013 | 21 | 0.100 |
Why?
|
| Glutamates | 2 | 2010 | 84 | 0.100 |
Why?
|
| Dominance, Cerebral | 5 | 1983 | 60 | 0.100 |
Why?
|
| Luminescent Proteins | 1 | 2013 | 141 | 0.100 |
Why?
|
| Resorcinols | 1 | 2013 | 5 | 0.100 |
Why?
|
| Receptors, Ionotropic Glutamate | 1 | 2013 | 1 | 0.100 |
Why?
|
| Cyclopropanes | 1 | 2013 | 25 | 0.100 |
Why?
|
| Injections | 2 | 2023 | 121 | 0.100 |
Why?
|
| Delphi Technique | 2 | 2023 | 135 | 0.100 |
Why?
|
| Optic Nerve | 2 | 1988 | 35 | 0.100 |
Why?
|
| Schizophrenia | 1 | 2017 | 530 | 0.100 |
Why?
|
| Glycine | 1 | 2013 | 93 | 0.090 |
Why?
|
| Adenoviridae | 1 | 2013 | 340 | 0.090 |
Why?
|
| Axonal Transport | 4 | 1997 | 30 | 0.090 |
Why?
|
| Photolysis | 1 | 2012 | 13 | 0.090 |
Why?
|
| Lysine | 3 | 2001 | 182 | 0.090 |
Why?
|
| Parasympathetic Nervous System | 2 | 2007 | 33 | 0.090 |
Why?
|
| Transfection | 1 | 2013 | 877 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2013 | 550 | 0.090 |
Why?
|
| Stilbenes | 1 | 2011 | 26 | 0.090 |
Why?
|
| Algorithms | 3 | 2011 | 1948 | 0.090 |
Why?
|
| 6-Cyano-7-nitroquinoxaline-2,3-dione | 2 | 2009 | 14 | 0.090 |
Why?
|
| Thyroid Neoplasms | 1 | 2016 | 441 | 0.090 |
Why?
|
| Brain Diseases | 1 | 2013 | 172 | 0.090 |
Why?
|
| Sensory Thresholds | 4 | 2001 | 51 | 0.090 |
Why?
|
| Amblyopia | 2 | 1982 | 7 | 0.080 |
Why?
|
| Perfusion | 1 | 2012 | 260 | 0.080 |
Why?
|
| Receptors, Neurotransmitter | 1 | 1990 | 24 | 0.080 |
Why?
|
| Ultraviolet Rays | 1 | 2011 | 192 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 249 | 0.080 |
Why?
|
| Stents | 1 | 2013 | 406 | 0.080 |
Why?
|
| Receptors, GABA-B | 1 | 2009 | 9 | 0.080 |
Why?
|
| Receptors, GABA-A | 1 | 2009 | 35 | 0.080 |
Why?
|
| Calbindin 2 | 1 | 2009 | 5 | 0.080 |
Why?
|
| Calbindins | 1 | 2009 | 16 | 0.080 |
Why?
|
| Quinoxalines | 1 | 2009 | 51 | 0.080 |
Why?
|
| Electron-Transferring Flavoproteins | 1 | 2009 | 2 | 0.080 |
Why?
|
| Homeostasis | 1 | 2012 | 459 | 0.080 |
Why?
|
| Dioxolanes | 1 | 2009 | 8 | 0.080 |
Why?
|
| Models, Animal | 1 | 2010 | 280 | 0.070 |
Why?
|
| Receptors, GABA | 1 | 2009 | 11 | 0.070 |
Why?
|
| Purines | 1 | 2009 | 91 | 0.070 |
Why?
|
| Models, Anatomic | 1 | 2009 | 87 | 0.070 |
Why?
|
| Anesthesia | 3 | 2000 | 173 | 0.070 |
Why?
|
| Staining and Labeling | 2 | 2008 | 155 | 0.070 |
Why?
|
| Nitric Oxide Synthase | 2 | 2000 | 123 | 0.070 |
Why?
|
| Dizocilpine Maleate | 1 | 2008 | 12 | 0.070 |
Why?
|
| Sexual Behavior | 2 | 2023 | 328 | 0.070 |
Why?
|
| Electron Transport Complex IV | 1 | 2008 | 46 | 0.070 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2008 | 193 | 0.070 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2009 | 195 | 0.070 |
Why?
|
| Ocular Physiological Phenomena | 3 | 1977 | 11 | 0.070 |
Why?
|
| Bacterial Proteins | 1 | 2013 | 878 | 0.070 |
Why?
|
| Time Perception | 3 | 1982 | 23 | 0.070 |
Why?
|
| Calcium-Binding Proteins | 1 | 2008 | 119 | 0.070 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2007 | 28 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2009 | 883 | 0.060 |
Why?
|
| Auditory Perception | 1 | 2008 | 104 | 0.060 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2007 | 137 | 0.060 |
Why?
|
| Macaca | 2 | 2005 | 85 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2009 | 448 | 0.060 |
Why?
|
| Smell | 1 | 2006 | 120 | 0.060 |
Why?
|
| Phytohemagglutinins | 3 | 1991 | 19 | 0.060 |
Why?
|
| Gap Junctions | 1 | 2006 | 146 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2301 | 0.060 |
Why?
|
| Young Adult | 3 | 2025 | 6922 | 0.060 |
Why?
|
| Wakefulness | 2 | 2003 | 128 | 0.060 |
Why?
|
| Drug Interactions | 1 | 2005 | 237 | 0.060 |
Why?
|
| Cell Size | 1 | 2005 | 71 | 0.050 |
Why?
|
| Mutation | 1 | 2016 | 4265 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 305 | 0.050 |
Why?
|
| Learning | 2 | 2014 | 289 | 0.050 |
Why?
|
| Potassium | 2 | 2001 | 224 | 0.050 |
Why?
|
| Macaca fascicularis | 2 | 2001 | 111 | 0.050 |
Why?
|
| Fourier Analysis | 3 | 2009 | 123 | 0.050 |
Why?
|
| Ligaments, Articular | 1 | 2023 | 39 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 1908 | 0.050 |
Why?
|
| Ankle Joint | 1 | 2023 | 42 | 0.050 |
Why?
|
| Leukocyte Count | 1 | 2023 | 209 | 0.050 |
Why?
|
| Risk Factors | 3 | 2025 | 5900 | 0.050 |
Why?
|
| Radiography | 1 | 2025 | 750 | 0.050 |
Why?
|
| Differential Threshold | 2 | 2000 | 11 | 0.050 |
Why?
|
| Motion Perception | 5 | 1991 | 100 | 0.050 |
Why?
|
| Administration, Rectal | 2 | 2013 | 13 | 0.050 |
Why?
|
| Knee Joint | 1 | 2023 | 161 | 0.050 |
Why?
|
| Neural Conduction | 5 | 1985 | 71 | 0.050 |
Why?
|
| Adult | 5 | 2025 | 27849 | 0.050 |
Why?
|
| Child | 2 | 2023 | 7273 | 0.050 |
Why?
|
| Electrodes, Implanted | 1 | 2003 | 196 | 0.050 |
Why?
|
| Recurrence | 1 | 2025 | 1188 | 0.040 |
Why?
|
| Vision Disorders | 1 | 1982 | 71 | 0.040 |
Why?
|
| Tobacco Use | 1 | 2021 | 29 | 0.040 |
Why?
|
| Pattern Recognition, Visual | 2 | 2000 | 158 | 0.040 |
Why?
|
| Microinjections | 2 | 1995 | 67 | 0.040 |
Why?
|
| Aged | 4 | 2023 | 20395 | 0.040 |
Why?
|
| Aging | 2 | 2023 | 725 | 0.040 |
Why?
|
| Spinal Cord | 1 | 2002 | 236 | 0.040 |
Why?
|
| Biomarkers | 1 | 2008 | 1905 | 0.040 |
Why?
|
| Cesium | 1 | 2001 | 16 | 0.040 |
Why?
|
| Middle Aged | 5 | 2023 | 27535 | 0.040 |
Why?
|
| Electrodes | 2 | 1991 | 97 | 0.040 |
Why?
|
| alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 1 | 2000 | 10 | 0.040 |
Why?
|
| Cholinergic Agonists | 1 | 2000 | 11 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2025 | 1925 | 0.040 |
Why?
|
| Carbachol | 1 | 2000 | 34 | 0.040 |
Why?
|
| Pons | 1 | 2000 | 25 | 0.040 |
Why?
|
| Ferrets | 1 | 2000 | 49 | 0.040 |
Why?
|
| Calcium Channels, T-Type | 1 | 2000 | 24 | 0.040 |
Why?
|
| Norepinephrine | 1 | 2000 | 166 | 0.040 |
Why?
|
| Calcium Signaling | 1 | 2001 | 138 | 0.040 |
Why?
|
| Magnesium | 1 | 2000 | 170 | 0.040 |
Why?
|
| Adolescent | 2 | 2025 | 9550 | 0.040 |
Why?
|
| Nicotinic Agonists | 1 | 2000 | 73 | 0.040 |
Why?
|
| Choline O-Acetyltransferase | 2 | 1997 | 24 | 0.040 |
Why?
|
| Vision, Monocular | 2 | 2001 | 15 | 0.040 |
Why?
|
| Periodicity | 1 | 2000 | 113 | 0.040 |
Why?
|
| Neuroprotective Agents | 1 | 2000 | 94 | 0.040 |
Why?
|
| HIV Serosorting | 1 | 2018 | 4 | 0.040 |
Why?
|
| Haplorhini | 2 | 1976 | 77 | 0.040 |
Why?
|
| France | 1 | 2018 | 52 | 0.040 |
Why?
|
| Kinetics | 2 | 1996 | 1463 | 0.040 |
Why?
|
| NADPH Dehydrogenase | 2 | 1994 | 11 | 0.030 |
Why?
|
| Reference Values | 3 | 1994 | 603 | 0.030 |
Why?
|
| Shrews | 1 | 1977 | 5 | 0.030 |
Why?
|
| Biological Transport, Active | 1 | 1997 | 98 | 0.030 |
Why?
|
| Blindness | 1 | 1977 | 39 | 0.030 |
Why?
|
| Iontophoresis | 1 | 1996 | 4 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 709 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2002 | 2705 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 1996 | 287 | 0.030 |
Why?
|
| Public Sector | 1 | 2016 | 13 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1160 | 0.030 |
Why?
|
| Private Sector | 1 | 2016 | 20 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2016 | 291 | 0.030 |
Why?
|
| Tupaiidae | 1 | 1975 | 1 | 0.030 |
Why?
|
| Strepsirhini | 1 | 1975 | 7 | 0.030 |
Why?
|
| Discrimination Learning | 3 | 1983 | 63 | 0.030 |
Why?
|
| Adaptation, Physiological | 2 | 1994 | 328 | 0.030 |
Why?
|
| Wheat Germ Agglutinins | 2 | 1993 | 15 | 0.030 |
Why?
|
| Electric Conductivity | 2 | 1987 | 142 | 0.030 |
Why?
|
| Career Choice | 1 | 2016 | 153 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 505 | 0.030 |
Why?
|
| Bicuculline | 1 | 1994 | 18 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2025 | 3450 | 0.020 |
Why?
|
| Sphincter of Oddi Dysfunction | 1 | 2012 | 1 | 0.020 |
Why?
|
| Survival Rate | 1 | 2016 | 1945 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 1993 | 281 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 2009 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 2787 | 0.020 |
Why?
|
| 2-Amino-5-phosphonovalerate | 1 | 1990 | 11 | 0.020 |
Why?
|
| N-Methylaspartate | 1 | 1990 | 45 | 0.020 |
Why?
|
| Aspartic Acid | 1 | 1990 | 62 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 494 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 3814 | 0.020 |
Why?
|
| Valine | 1 | 2009 | 46 | 0.020 |
Why?
|
| Eyelids | 2 | 1994 | 20 | 0.020 |
Why?
|
| Age Factors | 3 | 1981 | 1898 | 0.020 |
Why?
|
| Prognosis | 1 | 2016 | 3890 | 0.020 |
Why?
|
| Length of Stay | 1 | 2012 | 820 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2012 | 1727 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 1660 | 0.020 |
Why?
|
| Hospitalization | 1 | 2012 | 924 | 0.020 |
Why?
|
| Temporal Lobe | 2 | 1977 | 187 | 0.010 |
Why?
|
| Signal Transduction | 1 | 1996 | 3497 | 0.010 |
Why?
|
| Biophysical Phenomena | 1 | 1986 | 124 | 0.010 |
Why?
|
| Dark Adaptation | 1 | 1984 | 12 | 0.010 |
Why?
|
| Histocytochemistry | 2 | 1994 | 121 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2013 | 4546 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1987 | 661 | 0.010 |
Why?
|
| Ganglia | 2 | 1973 | 12 | 0.010 |
Why?
|
| Psychophysics | 1 | 1982 | 72 | 0.010 |
Why?
|
| Growth | 1 | 1982 | 42 | 0.010 |
Why?
|
| Sutures | 1 | 1982 | 58 | 0.010 |
Why?
|
| Photomicrography | 1 | 1981 | 7 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1981 | 422 | 0.010 |
Why?
|
| Biomechanical Phenomena | 1 | 1982 | 486 | 0.010 |
Why?
|
| Arousal | 1 | 2000 | 171 | 0.010 |
Why?
|
| Form Perception | 1 | 1980 | 36 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2013 | 9070 | 0.010 |
Why?
|
| Species Specificity | 1 | 2001 | 683 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2013 | 10128 | 0.010 |
Why?
|
| Nictitating Membrane | 1 | 1977 | 1 | 0.010 |
Why?
|
| Pyramidal Tracts | 1 | 1977 | 15 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 1978 | 219 | 0.010 |
Why?
|
| Cerebral Decortication | 1 | 1975 | 1 | 0.010 |
Why?
|
| Visual Field Tests | 1 | 1975 | 15 | 0.010 |
Why?
|
| Fixation, Ocular | 1 | 1974 | 49 | 0.010 |
Why?
|
| Dogs | 1 | 1975 | 632 | 0.010 |
Why?
|
| Environment | 1 | 1976 | 230 | 0.010 |
Why?
|
| Suture Techniques | 1 | 1994 | 137 | 0.010 |
Why?
|
| Wheat Germ Agglutinin-Horseradish Peroxidase Conjugate | 1 | 1993 | 3 | 0.010 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 1993 | 41 | 0.010 |
Why?
|
| Macula Lutea | 1 | 1973 | 17 | 0.010 |
Why?
|
| Nerve Degeneration | 1 | 1973 | 75 | 0.010 |
Why?
|
| Depth Perception | 1 | 1971 | 19 | 0.010 |
Why?
|
| Mathematics | 1 | 1971 | 178 | 0.010 |
Why?
|
| Light | 1 | 1972 | 286 | 0.010 |
Why?
|
| Darkness | 1 | 1979 | 47 | 0.000 |
Why?
|